High Glucose Induced Upregulation of Cyclin a Associating with a Short Survival of Patients with Cholangiocarcinoma: A Potential Target for Treatment of Patients with Diabetes Mellitus

References

• American Diabetes Association. Classification 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14–S31. doi:https://doi.org/10.2337/dc20-S002
   PubMed Web of Science ®Google Scholar
• Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23. doi:https://doi.org/10.1677/erc-09-0087
   PubMed Web of Science ®Google Scholar
• Suh S, Kim KW. Diabetes and cancer: cancer should be screened in routine diabetes assessment. Diabetes Metab J. 2019;43(6):733–43. doi:https://doi.org/10.4093/dmj.2019.0177
   PubMed Web of Science ®Google Scholar
• Wojciechowska J, Krajewski W, Bolanowski M, Kręcicki T, Zatoński T. Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes. 2016;124(5):263–75. doi:https://doi.org/10.1055/s-0042-100910
   PubMed Web of Science ®Google Scholar
• Chang SC, Yang WV. Hyperglycemia, tumorigenesis, and chronic inflammation. Crit Rev Oncol Hematol. 2016;108:146–53. doi:https://doi.org/10.1016/j.critrevonc.2016.11.003
   PubMed Web of Science ®Google Scholar
• Ma J, Wang J, Ge L, Long B, Zhang J. The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis. Acta Diabetol. 2019;56(10):1103–11. doi:https://doi.org/10.1007/s00592-019-01337-2
   PubMed Web of Science ®Google Scholar
• Yang I-P, Miao Z-F, Huang C-W, Tsai H-L, Yeh Y-S, Su W-C, Chang T-K, Chang S-f, Wang J-Y. High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy. Ther Adv Med Oncol. 2019;11:175883591986696. doi:https://doi.org/10.1177/1758835919866964
   Web of Science ®Google Scholar
• Fiorillo C, Quero G, Laterza V, Mascagni P, Longo F, Menghi R, Razionale F, Rosa F, Mezza T, Boskoski I, et al. Postoperative hyperglycemia affects survival after gastrectomy for cancer: a single-center analysis using propensity score matching. Surgery. 2020;167(5):815–20. doi:https://doi.org/10.1016/j.surg.2019.11.006
   PubMed Web of Science ®Google Scholar
• Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72(1):95–103. doi:https://doi.org/10.1016/j.jhep.2019.09.007
   PubMed Web of Science ®Google Scholar
• Petrick JL, Thistle JE, Zeleniuch-Jacquotte A, Zhang X, Wactawski-Wende J, Van Dyke AL, Stampfer MJ, Sinha R, Sesso HD, Schairer C, et al. Body mass index, diabetes and intrahepatic cholangiocarcinoma risk: the liver cancer pooling project and meta-analysis. Am J Gastroenterol. 2018;113(10):1494–505. doi:https://doi.org/10.1038/s41395-018-0207-4
   PubMed Web of Science ®Google Scholar
• Saengboonmee C, Seubwai W, Lert-Itthiporn W, Sanlung T, Wongkham S. Association of diabetes mellitus and cholangiocarcinoma: update of evidence and the effects of antidiabetic medication. Can J Diabetes. 2021;45(3):282–90. doi:https://doi.org/10.1016/j.jcjd.2020.09.008
   PubMed Web of Science ®Google Scholar
• Saengboonmee C, Seubwai W, Wongkham C, Wongkham S. Diabetes mellitus: possible risk and promoting factors of cholangiocarcinoma: association of diabetes mellitus and cholangiocarcinoma. Cancer Epidemiol. 2015;39(3):274–8. doi:https://doi.org/10.1016/j.canep.2015.04.002
   PubMed Web of Science ®Google Scholar
• Aungkulanon S, Tangcharoensathien V, Shibuya K, Bundhamcharoen K, Chongsuvivatwong V. Post universal health coverage trend and geographical inequalities of mortality in Thailand. Int J Equity Health. 2016;15(1):190. doi:https://doi.org/10.1186/s12939-016-0479-5
   PubMed Web of Science ®Google Scholar
• Saengboonmee C, Seubwai W, Pairojkul C, Wongkham S. High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation. Sci Rep. 2016;6:18995. doi:https://doi.org/10.1038/srep.
   PubMed Web of Science ®Google Scholar
• Saengboonmee C, Phoomak C, Supabphol S, Covington KR, Hampton O, Wongkham C, Gibbs RA, Umezawa K, Seubwai W, Gingras M-C, et al. NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells. Life Sci. 2020;262:118548:doi:https://doi.org/10.1016/j.lfs.2020.118548
   PubMed Web of Science ®Google Scholar
• Saengboonmee C, Seubwai W, Cha’on U, Sawanyawisuth K, Wongkham S, Wongkham C. Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-ĸB. Anticancer Res. 2017;37(1):115–23. doi:https://doi.org/10.21873/anticanres.11296
   PubMed Web of Science ®Google Scholar
• Phoomak C, Vaeteewoottacharn K, Silsirivanit A, Saengboonmee C, Seubwai W, Sawanyawisuth K, Wongkham C, Wongkham S. High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Sci Rep. 2017;7:43842. doi:https://doi.org/10.1038/srep43842
   PubMed Web of Science ®Google Scholar
• Luo C, Liang J, Sharabi K, Hatting M, Perry EA, Tavares CDJ, Goyal L, Srivastava A, Bilodeau M, Zhu AX, et al. Obesity/type 2 diabetes-associated liver tumors are sensitive to cyclin D1 deficiency. Cancer Res. 2020;80(16):3215–21. doi:https://doi.org/10.1158/0008-5472.Can-20-0106
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115. doi:https://doi.org/10.1038/nrc.2016.138
   PubMed Web of Science ®Google Scholar
• Huang C-Y, Hsieh F-S, Wang C-Y, Chen L-J, Chang S-S, Tsai M-H, Hung M-H, Kuo C-W, Shih C-T, Chao T-I, et al. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur J Cancer. 2018;102:10–22. doi:https://doi.org/10.1016/j.ejca.2018.07.010
   PubMed Web of Science ®Google Scholar
• Sittithumcharee G, Suppramote O, Vaeteewoottacharn K, Sirisuksakun C, Jamnongsong S, Laphanuwat P, Suntiparpluacha M, Matha A, Chusorn P, Buraphat P, et al. Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity. Hepatology. 2019;70(5):1614–30. doi:https://doi.org/10.1002/hep.30704
   PubMed Web of Science ®Google Scholar
• Song X, Liu X, Wang H, Wang J, Qiao Y, Cigliano A, Utpatel K, Ribback S, Pilo MG, Serra M, et al. Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma. Clin Cancer Res. 2019;25(1):403–13. doi:https://doi.org/10.1158/1078-0432.Ccr-18-0284
   PubMed Web of Science ®Google Scholar
• Saisomboon S, Kariya R, Vaeteewoottacharn K, Wongkham S, Sawanyawisuth K, Okada S. Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model. Heliyon. 2019;5(5):e01675. doi:https://doi.org/10.1016/j.heliyon.2019.e01675
   PubMed Web of Science ®Google Scholar
• Sripa B, Seubwai W, Vaeteewoottacharn K, Sawanyawisuth K, Silsirivanit A, Kaewkong W, Muisuk K, Dana P, Phoomak C, Lert-Itthiporn W, et al. Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient. Hum Cell. 2020;33(3):695–708. doi:https://doi.org/10.1007/s13577-020-00334-w
   PubMed Web of Science ®Google Scholar
• McCarty KS, Jr., Miller LS, Cox EB, Konrath J, McCarty KSSr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716–21.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020;20(11):629–44. doi:https://doi.org/10.1038/s41568-020-0295-5
   PubMed Web of Science ®Google Scholar
• Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17(5):280–92. doi:https://doi.org/10.1038/nrm.2016.27
   PubMed Web of Science ®Google Scholar
• Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol. 2013;14(5):297–306. doi:https://doi.org/10.1038/nrm3567
   PubMed Web of Science ®Google Scholar
• Kolupaeva V, Janssens V. PP1 and PP2A phosphatases-cooperating partners in modulating retinoblastoma protein activation. Febs J. 2013;280(2):627–43. doi:https://doi.org/10.1111/j.1742-4658.2012.08511.x
   PubMed Web of Science ®Google Scholar
• Kawashima R, Haisa M, Kimura M, Takaoka M, Shirakawa Y, Takeda H, Uetsuka H, Gunduz M, Nagai N, Tanaka N, et al. Cyclin A correlates with the sensitivity of human cancer cells to cytotoxic effects of 5-FU. Int J Oncol. 2004;24(2):273–8.
   PubMed Web of Science ®Google Scholar
• Nilsson P, Lenander C, Rubio C, Auer G, Ljungqvist O, Glimelius B. Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep. 2006;16:443–9. doi:https://doi.org/10.3892/or.16.3.443
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, Sanchez JJ, Ballestin C, Diez A, Sanchez-Verde L, Alameda F, Sanchez-Cespedes M. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res. 2004;10(24):8486–92. doi:https://doi.org/10.1158/1078-0432.CCR-04-0771
   PubMed Web of Science ®Google Scholar
• Huang J-X, Shen S-LE, Lin MEI, Xiao WEI, Chen W-C, Lin M-S, Yu HONG, Chen PING, Qian R-YU. Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett. 2012;4(4):607–11. doi:https://doi.org/10.3892/ol.2012.814
   PubMed Web of Science ®Google Scholar
• Cybulski M, Jarosz B, Nowakowski A, Jeleniewicz W, Kutarska E, et al. Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer. Anticancer Res. 2015;35:1715–21.
   PubMed Web of Science ®Google Scholar
• Cooper WA, Kohonen-Corish MRJ, McCaughan B, Kennedy C, Sutherland RL, Lee CS. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology. 2009;55(1):28–36. doi:https://doi.org/10.1111/j.1365-2559.2009.03331.x
   PubMed Web of Science ®Google Scholar
• Bahnassy AA, Zekri A-RN, El-Houssini S, El-Shehaby AMR, Mahmoud MR, Abdallah S, El-Serafi M. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 2004;4:22. doi:https://doi.org/10.1186/1471-230x-4-22
   PubMed Web of Science ®Google Scholar
• Saarilahti K, Kajanti M, Kouri M, Aaltonen L-M, Franssila K, Joensuu H. Cyclin A and Ki-67 expression as predictors for locoregional recurrence and outcome in laryngeal cancer patients treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57(4):986–95. doi:https://doi.org/10.1016/s0360-3016(03)00736-3
   PubMed Web of Science ®Google Scholar
• Aaltomaa S, Eskelinen M, Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient ­survival. Prostate. 1999;38(3):175–82. doi:https://doi.org/10.1002/(sici)1097-0045(19990215)38:3 < 175::aid-pros1 > 3.0.co;2-#
   PubMed Web of Science ®Google Scholar
• Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirstrom K, Blomqvist C, Amini R-M, Fjallskog M-L. Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2501–6. doi:https://doi.org/10.1158/1055-9965.EPI-09-0169
   PubMed Web of Science ®Google Scholar
• Bukholm IR, Bukholm G, Nesland JM. Coexpression of cyclin A and beta-catenin and survival in breast cancer patients. Int J Cancer. 2001;94(1):148–9. doi:https://doi.org/10.1002/ijc.1432
   PubMed Web of Science ®Google Scholar
• Bukholm IR, Husdal A, Nesland JM, Langerod A, Bukholm G. Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time. Breast Cancer Res Treat. 2003;80(2):199–206. doi:https://doi.org/10.1023/a:1024527220362
   PubMed Web of Science ®Google Scholar
• Husdal A, Bukholm G, Bukholm IR. The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cell Oncol. 2006;28(3):107–16. doi:https://doi.org/10.1155/2006/721919
   PubMed Web of Science ®Google Scholar
• Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer. 2002;86(3):402–8. doi:https://doi.org/10.1038/sj.bjc.6600072
   PubMed Web of Science ®Google Scholar
• Poikonen P, Sjöström J, Amini R-M, Villman K, Ahlgren J, Blomqvist C. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer. 2005;93(5):515–9. doi:https://doi.org/10.1038/sj.bjc.6602735
   PubMed Web of Science ®Google Scholar
• Hayashi T, Adachi K, Ohba S, Hirose Y. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. J Neurooncol. 2013;115(2):169–78. doi:https://doi.org/10.1007/s11060-013-1220-5
   PubMed Web of Science ®Google Scholar
• Jackman KM, Frye CB, Hunger SP. Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(4):772–8. doi:https://doi.org/10.1002/pbc.21386
   PubMed Web of Science ®Google Scholar
• Soner BC, Aktug H, Acikgoz EDA, Duzagac F, Guven UMMU, Ayla SULE, Cal CAG, Oktem G. Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol. Int J Mol Med. 2014;34(5):1249–56. doi:https://doi.org/10.3892/ijmm.2014.1930
   PubMed Web of Science ®Google Scholar
• Li W, Zhang X, Sang H, Zhou Y, Shang C, Wang Y, Zhu H. Effects of hyperglycemia on the progression of tumor diseases. J Exp Clin Cancer Res. 2019;38(1):327 doi:https://doi.org/10.1186/s13046-019-1309-6
   PubMed Web of Science ®Google Scholar
• Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y, et al. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers. Cancer Sci. 2012;103(2):252–61. doi:https://doi.org/10.1111/j.1349-7006.2011.02138.x
   PubMed Web of Science ®Google Scholar
• Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, Francis H, Marucci L, Sterpetti P, Ginanni-Corradini S, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169(3):877–88. doi:https://doi.org/10.2353/ajpath.2006.050464
   PubMed Web of Science ®Google Scholar
• Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, Trepo E, Overvad K, Roswall N, Tjønneland A, Boutron-Ruault MC, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol. 2013;24(9):2449–55. doi:https://doi.org/10.1093/annonc/mdt204
   PubMed Web of Science ®Google Scholar
• Abrahami D, Douros A, Yin H, Yu OH, Faillie J-L, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 2018;363:k4880. doi:https://doi.org/10.1136/bmj.k4880
   PubMed Web of Science ®Google Scholar
• Thamrongwaranggoon U, Seubwai W, Phoomak C, Sangkhamanon S, Cha’on U, Boonmars T, Wongkham S. Targeting hexokinase II as a possible therapy for cholangiocarcinoma. Biochem Biophys Res Commun. 2017;484(2):409–15. doi:https://doi.org/10.1016/j.bbrc.2017.01.139
   PubMed Web of Science ®Google Scholar
• Thonsri U, Seubwai W, Waraasawapati S, Sawanyawisuth K, Vaeteewoottacharn K, Boonmars T, Cha’on U. Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis. Histol Histopathol. 2017;32(5):503–10. doi:https://doi.org/10.14670/hh-11-819
   PubMed Web of Science ®Google Scholar
• Thonsri U, Seubwai W, Waraasawapati S, Wongkham S, Boonmars T, Cha’on U, Wongkham C. Antitumor effect of shikonin, a PKM2 inhibitor, in cholangiocarcinoma cell lines. Anticancer Res. 2020;40(9):5115–24. doi:https://doi.org/10.21873/anticanres.14515
   PubMed Web of Science ®Google Scholar